<DOC>
	<DOCNO>NCT00120783</DOCNO>
	<brief_summary>This study investigate whether calibrate reduction antiretroviral drug pressure could stabilize evolution pathogenic potential resistant HIV virus .</brief_summary>
	<brief_title>Efficacy Tolerability Antiretroviral Bi-Therapy HIV Infected Patients With Multidrug Resistance</brief_title>
	<detailed_description>In patient HIV multidrug resistance , maintain fail full-dose HAART regimen usually result significant drug toxicity continue accumulation resistance mutation preclude future therapeutic option . In contrast , treatment interruption provokes reemergence wild-type virus full replicative pathogenic capacity . The researcher investigate whether calibrate reduction drug pressure could stabilize evolution pathogenic potential resistant virus . A prospective pilot study conduct patient receive protease inhibitor-based HAART resistance genotype predict less two active drug accord 2002 ANRS algorithm , CD4 count equal 100/mm3 plasma HIV RNA equal 5 log/ml . The treatment low-dose IDV/RTV ( 200/100 BID ) 3TC 150mg BID . IDV dos adjust week 4 ensure Cmin 250+/-100ng/ml , , base panel multi-PI resistant virus , calculate yield inhibitory quotient ( Cmin/IC50 ) 0.50 . Primary end-points 25 % decrease CD4 count ( immunological failure–IF ) , 0.7 log increase plasma HIV RNA ( virological failure–VF ) two consecutive monthly visit 24-week study . Inclusions stop total number failure ( VF+IF ) reach 7</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 infection confirm Western Blot Karnofsky score equal 70 CD4 equal 200/mm3 Plasma viral RNA equal 10 000 copies/ml 100 000 copies/ml . Stability plasma viral load CD4during last 3 month failure two antiretroviral regimen 2 PI one NNRTI New efficacy drug genotype available Treatment hand 3 antiretroviral drug one PI since 3 month . Written inform consent Pregnancy Hemoglobin 8g/dL Neutrophils 750/mm3 ASAT , ALAT 5N Hepatic insufficiency ( prothrombin 50 % ) Acute opportunistic infection Immunotherapy Treatment active antiretroviral regimen Treatment enzyme inductor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Treatment Failure</keyword>
	<keyword>HIV infection</keyword>
</DOC>